2-24 | More than two years after drug approved, only 180 people globally have received it. Geneva, 24 February 2016 Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of US$1,700 per treatment course.
High vaccine prices hamper immunisation efforts in Africa, but are missing from agenda of key vaccination conference
2-23 | Ministerial Conference on Immunisation in Africa presses countries to do more, but gives free pass to pharmaceutical companies charging inflated vaccine prices.
There’s still time to stop the TPP from cutting off the critical lifeline of affordable generic medicines
2-4 | As representatives from the United States and 11 other Pacific-Rim countries gather in New Zealand today to sign the Trans-Pacific Partnership (TPP) trade agreement, the fight to protect access to medicines in TPP countries is intensifying at the national level, with legislative processes starting that will determine if the deal is finally ratified and implemented.Doctors Without Borders/Médecins Sans Frontières (MSF) is calling on the more than 800 million people living in TPP countries to urge their governments to reject the deal unless harmful provisions that lock in high drug
11-12 | MSF Asks Supporters in Southeast Asia to TURN RED for more affordable pneumonia vaccine Hong Kong/Jakarta, 12 November 2015—The international medical humanitarian organisation Médecins Sans Frontières/Doctors Without Borders (MSF) launched ‘A Fair Shot’ online campaign today on World Pneumonia Day.
7-28 | The clock is ticking. Asian countries are under time pressure to sacrifice public health interests to get final agreement on a trade deal. The Trans-Pacific Partnership (TPP), which is currently being negotiated between the US and 11 other Pacific Rim nations – including Malaysia, Singapore, Brunei, Japan and Vietnam – is on track to become the most harmful trade pact ever for access to low-cost medicines in developing countries. Last month, the U.S.